Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a core emphasis on leveraging the immune system to treat malignancies and prevent or control infectious threats. Its primary value driver is the development and commercialization of immune-enhancing biologics designed to activate both innate and adaptive immune responses.
The company’s lead product is Anktiva® (nogapendekin alfa inbakicept), an interleukin-15 (IL‑15) superagonist complex that has been approved in the United States for certain patients with BCG-unresponsive non–muscle-invasive bladder cancer with carcinoma in situ. ImmunityBio’s strategy centers on combination immunotherapy and durable immune memory, positioning the company distinctively relative to checkpoint inhibitor–focused peers. ImmunityBio was formed through the merger of NantKwest, Inc. and ImmunityBio in 2021, consolidating oncology-focused immunotherapy assets originally developed within the NantWorks ecosystem founded by Patrick Soon-Shiong.
Business Operations
ImmunityBio’s operations are primarily organized around oncology biologics development and commercialization, with additional programs targeting infectious diseases. Revenue generation currently derives from early-stage commercial sales of Anktiva®, alongside collaboration and licensing activities, while the majority of operations remain focused on clinical development and regulatory expansion of its pipeline. The company conducts research, clinical trials, regulatory affairs, and manufacturing oversight internally and through contract partners.
The company controls proprietary cytokine fusion and delivery technologies designed to stimulate natural killer cells and T cells without inducing excessive toxicity. Manufacturing capabilities include access to biologics production infrastructure in the United States, supporting both clinical and commercial supply. ImmunityBio maintains relationships with academic institutions, government agencies, and research hospitals to support late-stage clinical trials and combination therapy studies. Data on additional material joint ventures beyond wholly owned subsidiaries is inconclusive based on available public sources.
Strategic Position & Investments
ImmunityBio’s strategic direction is centered on expanding the clinical and commercial footprint of Anktiva® across additional bladder cancer indications and into other solid tumors and hematologic malignancies. Growth initiatives include pursuing label expansions, combination regimens with checkpoint inhibitors and chemoradiation, and global regulatory approvals. The company has also emphasized pandemic preparedness and immune-restorative platforms applicable to viral infections.
The company’s asset base largely stems from internal development and the prior consolidation of NantKwest, Inc., rather than a strategy of frequent third-party acquisitions. Investment focus remains on late-stage clinical trials, manufacturing scale-up, and post-approval studies. ImmunityBio continues to evaluate emerging immuno-oncology applications of IL‑15–based therapeutics, though details on material minority investments or external portfolio companies are limited in public disclosures.
Geographic Footprint
ImmunityBio is headquartered in Culver City, California, and operates primarily within the United States, where its research, development, regulatory, and initial commercial activities are concentrated. Clinical trials are conducted across multiple U.S. sites, with additional participation from select international locations depending on study design.
The company maintains an international presence through global clinical trial enrollment and regulatory planning, particularly in Europe and parts of Asia, where bladder cancer and solid tumor indications represent significant markets. While ImmunityBio does not currently report large-scale overseas manufacturing or sales operations, it has articulated an intent to pursue broader international commercialization through partnerships and regulatory submissions.
Leadership & Governance
ImmunityBio was founded by Patrick Soon-Shiong, whose long-standing vision emphasizes restoring immune function to achieve durable cancer control. The current leadership team combines experience in oncology drug development, regulatory strategy, and biologics manufacturing, with a governance approach focused on long-term platform development rather than single-asset monetization.
Key executives include:
- Richard Adcock – Chief Executive Officer
- Patrick Soon-Shiong – Founder and Executive Chairman
- Mark A. Cobb – Chief Financial Officer
- Ned B. McCracken – Chief Operating Officer
- Burton Goldfield – President
Leadership communications consistently highlight a strategy centered on immune system activation, combination therapy, and the pursuit of curative-intent cancer treatments, as reflected in public filings and investor communications.